Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

ATOS Atossa Therapeutics Inc

0,87

0,0443 (5,37%)

22 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Atossa Therapeutics Charts.

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Atossa Therapeutics Charts.

News Atossa Therapeutics Inc

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer
Montag 6 Januar 2025 (2 Wochen vor) • GlobeNewswire Inc.

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Donnerstag 12 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Mittwoch 11 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 10 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
Dienstag 10 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
Montag 9 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Donnerstag 21 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Mittwoch 20 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 19 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Dienstag 19 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Dienstag 12 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Freitag 8 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Atossa Therapeutics Inc News-Artikel

Kiromic BioPharma

Freeport McMoRan

Caisse Depots Et Consign...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen